Richard Love - PAREXEL International Independent Director

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

  Director
Mr. Richard L. Love is an Independent Director of Parexel International Corporationrationration. is a member of the Compensation Committee, the Nominating and Corporationrationrate Governance Committee and the Human Resources Committee. Since January 2007, Mr. Love has served as a partner of Translational Accelerator Venture Fund, an investment fund. Since October 2016, he has served as Interim President and Chief Executive Officer of CTI Biopharma, Inc., a biopharmaceutical company. From January 2003 to January 2007, he served as Chief Operating Officer of Translational Genomics Research Institute, a medical research organization, and from January 2002 to December 2004, he served as a director of ILEX Oncology, an oncology focused pharmaceutical company. From October 1994 to January 2002, Mr. Love served as President and Chief Executive Officer of ILEX Oncology. From 1991 to 1994, he served as Chief Operating Officer of the Cancer Therapy and Research Center, a cancer treatment center focused on the clinical evaluation of new agents. From 1983 to 1991, Mr. Love served as Chief Executive Officer of Triton Biosciences, Inc., a biotechnology company. Mr. Love currently serves as a director of CTI Biopharma, Inc., SyndevRx Inc., Applied Microarrays Inc., Cancer Prevention Pharmaceuticals, Inc. and CerRx Inc., and as a Manager on the Board of Managers of PMED Management LLC.
Age: 72  Director Since 2002      
781 487-9900  http://www.parexel.com

Richard Love Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Theodore SamuelstoPerrigo Company plc
2017
Shikha SharmaDr Reddys Laboratories Ltd
2019
Alan GarberVertex Pharmaceuticals Incorpor
2017
Meng MeiSinovac Biotech Ltd
2012
Jeffrey SmithPerrigo Company plc
2017
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Alfred GilmanRegeneron Pharmaceuticals
1990
Gary KunklePerrigo Company plc
2009
Christine PoonRegeneron Pharmaceuticals
2010
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
David GreenwayVertex Pharmaceuticals Incorpor
2017
Shan FuSinovac Biotech Ltd
N/A
Fei WangOrigin Agritech Limited
2019
Sridar IyengarDr Reddys Laboratories Ltd
2011
Prasad MenonDr Reddys Laboratories Ltd
2019
Michael BrownRegeneron Pharmaceuticals
1991
William SteereZoetis
2013
Jacqualyn FousePerrigo Company plc
2012
Yuchun LeeVertex Pharmaceuticals Incorpor
2012

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

TWTR   
Purchased over 50 shares of
few hours ago
Traded for 1.0
MGTI   
Purchased over 50 shares of
few hours ago
Traded for 1.0
PVCT   
Purchased over 10K shares of
few hours ago
Traded for 1.0
BTSC   
Purchased over 10K shares of
few hours ago
Traded for 1.0
ALNY   
Purchased few shares of
few hours ago
Traded for 1.0
Additionally take a look at Your Equity Center. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Search macroaxis.com